IVZ Stock Recent News
IVZ LATEST HEADLINES
Driven by solid inflows and market appreciation, IVZ witnesses an improvement in AUM in Q3. This is likely to have aided the company's earnings.
Beyond analysts' top -and-bottom-line estimates for Invesco (IVZ), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Invesco (IVZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invesco (IVZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ATLANTA , Oct. 9, 2024 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ) today reported preliminary month-end assets under management (AUM) of $1,795.6 billion, an increase of 2.5% versus previous month-end.
In a notable move within the investment community, Invesco Ltd. (Trades, Portfolio) recently adjusted its holdings in Veeco Instruments Inc. (VECO, Financial), a key player in the semiconductor sector.
The high-flying Nasdaq-tracking ETF isn't always the best choice for most investors.
Invesco Mortgage had a slightly underperforming quarter, with a 2.3% variance in BV and core earnings/EAD matching closely to projections. IVR's mis-timed asset purchases and decreased hedging coverage ratio negatively impacted BV, while core earnings remained stable due to offsetting factors. IVR is priced at a discount compared to peers due to significant BV and economic losses over the past 24 months, despite strong core earnings.
A solid AUM balance, global footprint and efforts to bolster operating efficiency are expected to continue supporting IVZ amid weak top-line performance.